Last 31 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 279.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.19 | 10.77 | 5.94 | 4.68 | 5.39 | 4.49 | 3.66 | 10.32 | 9.30 | 7.08 | 7.60 | 8.96 | 20.00 | 8.26 | 5.55 | 5.50 | 1.64 | 1.04 | 1.36 | 1.94 | 1.77 |
| — | +139.7% | +62.1% | -54.7% | -42.1% | -36.6% | -51.8% | +15.2% | -53.5% | -14.2% | +37.1% | +62.9% | +1116.5% | +692.7% | +306.5% | +183.7% | -7.0% | -63.2% | -66.0% | -82.2% | -77.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -2159.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -2159.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.8% | -19.3% | -16.1% | -14.7% | -22.4% | -18.3% | -20.1% | -27.7% | -22.0% | -15.0% | -11.6% | -11.0% | -21.3% | -22.3% | -15.3% | -15.6% | -11.5% | -8.9% | -9.7% | -7.9% | -8.4% |
| — | -5.3% | +19.9% | +47.0% | -2.1% | -22.2% | -72.9% | -151.0% | -3.3% | +32.8% | +24.1% | +29.2% | -84.6% | -150.6% | -58.1% | -96.3% | -37.8% | -10.7% | -38.4% | -6.6% | -42.0% | |
| ROA | -58.3% | -16.9% | -14.7% | -13.5% | -20.3% | -16.8% | -17.8% | -23.7% | -19.7% | -13.9% | -10.9% | -10.2% | -18.2% | -19.5% | -13.8% | -14.3% | -10.8% | -8.3% | -8.9% | -7.5% | -7.9% |
| — | -0.9% | +17.2% | +43.0% | -3.0% | -20.9% | -62.7% | -131.5% | -8.3% | +29.0% | +20.7% | +28.3% | -68.7% | -135.7% | -54.7% | -91.7% | -36.9% | -8.9% | -33.8% | -4.1% | -41.4% | |
| ROIC | — | — | — | — | -2648.3% | -5959.9% | — | — | — | — | — | — | — | — | — | — | -2365.6% | -266.3% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | — | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| — | — | -39.6% | — | — | — | -37.7% | -85.6% | -95.7% | -95.9% | -93.4% | -87.7% | -46.4% | -35.8% | -33.1% | -33.3% | -19.6% | -42.9% | -42.3% | -35.3% | -34.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.09 | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 | 7.23 | 6.82 | 9.34 | 11.01 | 13.41 | 21.48 | 11.52 | 14.87 | 19.86 |
| — | -41.0% | -18.6% | +160.7% | +19.1% | -5.8% | -18.5% | -72.7% | +5.2% | +92.0% | +46.7% | +101.0% | -46.0% | -68.3% | -18.9% | -25.9% | -32.5% | +14.5% | -47.1% | -42.9% | -43.5% | |
| Quick Ratio | 9.09 | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 | 7.23 | 6.82 | 9.34 | 11.01 | 13.41 | 21.48 | 11.52 | 14.87 | 19.86 |
| — | -41.0% | -18.6% | +160.7% | +19.1% | -5.8% | -18.5% | -72.7% | +5.2% | +92.0% | +46.7% | +101.0% | -46.0% | -68.3% | -18.9% | -25.9% | -32.5% | +14.5% | -47.1% | -42.9% | -43.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMVT stock.
Immunovant, Inc.'s current P/E is -12.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Immunovant, Inc.'s business trajectory between earnings reports.